Rockwell Medical, Inc.
RMTI, a fully-integrated biopharmaceutical company
targeting end-stage renal disease (ESRD) and chronic kidney disease
(CKD) with innovative products and services for the treatment of iron
replacement, secondary hyperparathyroidism and hemodialysis,
announced today that the Phase 3 CRUISE-1 and CRUISE-2 clinical
abstract submitted as a Late-Breaking Clinical Trial (LBCT) to the
ASN LBCT subcommittee has been accepted for poster presentation at
the ASN Kidney Week 2013 Annual Meeting, November 7-10 in Atlanta,
GA.
The abstract will be presented under the Late-Breaking Posters as
"Continuous, Maintenance Iron Therapy Using Soluble Ferric
Pyrophosphate Citrate Chelate (SFP, Triferic(TM)) Infusion via
Hemodialysate in CKD-HD: Phase III CRUISE Studies".
The Company will provide further information, including date, time
and presenter prior to the ASN annual meeting taking place November
7-10 in Atlanta, GA.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in